VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener

MapLight Therapeutics, Inc. (MPLT) Total Return Calculator with Dividends Reinvested

MapLight Therapeutics, Inc.

Popular:

The total return for MapLight Therapeutics, Inc. (MPLT) stock is +62.63% over the past 12 months. So far it's up 62.63% this year. The 5-year total return is +62.63%, meaning $10,000 invested in MPLT stock 5 years ago would be worth $16,263 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in MPLT 1 year ago, it would be worth $16,263 today — you'd have gained $6,263.

With Dividends Reinvested$16,263+62.63%

Price Only (No DRIP)$16,263+62.63%

Period2026-03-03 → 2026-05-14

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in MPLT

1Y$16,263+$6,263 (+62.6%)62.6% CAGR

3Y$16,263+$6,263 (+62.6%)17.6% CAGR

5Y$16,263+$6,263 (+62.6%)10.2% CAGR

10Y$16,263+$6,263 (+62.6%)5.0% CAGR

15Y$16,263+$6,263 (+62.6%)3.3% CAGR

20Y$16,263+$6,263 (+62.6%)2.5% CAGR

30Y$16,263+$6,263 (+62.6%)1.6% CAGR

MapLight Therapeutics, Inc. did not pay dividends during this period. Total return = price return.

Loading MPLT total return...

As of 2026-05-15

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	+62.63%	—	+62.63%	—	$16,263
1Y	+62.63%	62.63%	+62.63%	—	$16,263
3Y	+62.63%	17.60%	+62.63%	—	$16,263
5Y	+62.63%	10.22%	+62.63%	—	$16,263
10Y	+62.63%	4.98%	+62.63%	—	$16,263
15Y	+62.63%	3.30%	+62.63%	—	$16,263
20Y	+62.63%	2.46%	+62.63%	—	$16,263
30Y	+62.63%	1.63%	+62.63%	—	$16,263

Risk & Highlights

Max Drawdown-14.72%2026-04-22 → 2026-05-08

MPLT outperformed the S&P 500 by 35.30pp over the past year (+62.63% vs +27.33%).

Loading summary...

MPLT Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
MPLTMapLight Therapeutics, Inc.	$1.3B	+8.4%	+62.6%	+62.6%	—	+62.6%	+62.6%	+62.6%
ACNBACNB Corporation	$544M	+2.8%	+12.1%	+22.7%	+3.3pp	+91.0%	+105.4%	+179.5%
PTGXProtagonist Therapeutics, Inc.	$6.8B	+0.8%	+21.1%	+141.1%	—	+306.4%	+246.4%	+802.1%
TERNTerns Pharmaceuticals, Inc.	$4.8B	+0.5%	+32.0%	+1804.7%	—	+346.1%	+232.8%	+187.9%
ACLXArcellx, Inc.	$6.7B	+0.2%	+81.7%	+95.0%	—	+164.8%	+584.9%	+584.9%
NRXPNRx Pharmaceuticals, Inc.	$89M	+28.4%	+22.5%	+41.4%	—	-53.9%	-98.6%	-96.7%
SAVACassava Sciences, Inc.	$94M	—	-6.5%	+4.0%	—	-48.4%	-66.6%	-19.5%
ACADACADIA Pharmaceuticals Inc.	$3.8B	+0.3%	-15.5%	+28.7%	—	-0.1%	+1.5%	-26.4%
INVAInnoviva, Inc.	$1.7B	-5.5%	+15.0%	+26.9%	—	+77.1%	+77.6%	+114.4%
PRAXPraxis Precision Medicines, Inc.	$10.0B	+0.6%	+20.6%	+831.3%	—	+2032.8%	+6.2%	-17.1%
NRXSNeurAxis, Inc.	$103M	+16.3%	+87.2%	+267.8%	—	+39.2%	+39.2%	+39.2%

Compare:MPLT vs ACNB MPLT vs PTGX MPLT vs TERN MPLT vs ACNB vs PTGX

About MPLT Dividend Returns

MapLight Therapeutics, Inc. (MPLT) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of MPLT over the past year?

MapLight Therapeutics, Inc. (MPLT) delivered a return of 62.63% over the past year. Since MPLT does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in MPLT be worth today?

A $10,000 investment in MapLight Therapeutics, Inc. one year ago would be worth $16,263 today, representing a gain of $6,263.

Q3Does MPLT pay dividends?

MapLight Therapeutics, Inc. (MPLT) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For MPLT, the total return equals the price-only return.

Q4Did MPLT beat the S&P 500?

Yes, MapLight Therapeutics, Inc. (MPLT) outperformed the S&P 500 by 35.30 percentage points over the past year. MPLT delivered a total return of 62.63%, compared to the S&P 500's 27.33%. This 35.30pp alpha means investors in MPLT earned more than a passive S&P 500 index fund.

Q5What is MPLT's worst drawdown?

MapLight Therapeutics, Inc. (MPLT) experienced a maximum drawdown of -14.72% over the past year, declining from its peak on 2026-04-22 to its trough on 2026-05-08. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is MPLT's long-term total return over 10, 20, or 30 years?

Here are MapLight Therapeutics, Inc. (MPLT)'s long-term returns with dividends reinvested. Over 10 years, the total return is 62.6% (5.0% CAGR) — $10,000 would have grown to $16,263. Over 20 years: 62.6% total return (2.5% CAGR) — $10,000 → $16,263. Over 30 years: 62.6% total return (1.6% CAGR) — $10,000 → $16,263. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.